Daver N et. al. A phase 1b/2 study of the CD123-targeting antibody-drug conjugate IMGN632 as monotherapy or in combination with venetoclax and azacitidine for patients with CD123-positive acute myeloid leukemia. ASH 2022;Abstract 4440.
Davar N et. al. Venetoclax in combination with gilteritinib demonstrates molecular clearance of FLT3 mutation in relapsed/refractory FLT3-mutated acute myeloid leukemia. ASH 2022;Abstract 691.
Dinardo CD et al. Postinfectious epigenetic immune modifications - A double-edged sword. N Engl J Med 2021;384(3):261-70. Abstract
Dinardo CD et al. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia. J Clin Oncol 2021;39(5):2768-78. Abstract
Geissler K et al. Pharmacokinetic exposure equivalence and preliminary efficacy and safety from a randomized crossover phase 3 study of an oral hypomethylating agent DEC-C compared to IV decitabine in AML patients. EHA 2022;Abstract P573.
Issa N et al. The histone demethylase KDM6B is a genetic dependency of NOTCH1-driven T-ALL. ASH 2022;Abstract 782.
Konopleva M et. al. Sex-biased ZRSR2 mutations in myeloid malignancies impair plasmacytoid dendritic cell activation and apoptosis. Cancer Discovery 2022;12(2):522-41. Abstract
Pratz KW et al. Cost effectiveness analysis of venetoclax plus azacitidine versus azacitidine in newly diagnosed adult patients with acute myeloid leukemia who are ineligible for intensive chemotherapy from a united states payer perspective. ASH 2022;Abstract 112.
Sharman JP et al. Acalabrutinib ± obinutuzumab vs obinutuzumab + chlorambucil in treatment-naive chronic lymphocytic leukemia: 5-year follow-up of ELEVATE-TN. EHA 2022;Abstract P525.
Walker AR et al. Entospletinib in combination with induction chemotherapy in previously untreated acute myeloid leukemia: Response and predictive significance of HOXA9 and MEIS1 expression. Clin Cancer Res 2020;26(22):5852-59. Abstract
Walker AR et al. Results of a phase 1b/2 study of entospletinib (GS-9973) monotherapy and in combination with induction chemotherapy in newly diagnosed patients with acute myeloid leukemia. EHA 2018;Abstract S118.